A patient tests positive for HIV Exhibits

A. Antiretroviral therapy (ART), including dolutegravir and lamivudine, inhibits HIV replication, reducing viral load to undetectable levels, which is a primary goal of treatment. This aligns with the patient’s regimen, as suppressing viral load prevents disease progression and reduces transmission risk. B. Dolutegravir and lamivudine can cause side effects such as headache, nausea, vomiting, and anorexia, which are well-documented in clinical data. Educating the patient about these potential effects is crucial for adherence and managing expectations. C. ART does not have zero side effects. Clinical evidence shows dolutegravir and lamivudine can cause adverse effects, including gastrointestinal issues and, rarely, liver problems, making this statement incorrect for patient education. D. While dolutegravir may cause insomnia in some patients, it is not a universal effect requiring nighttime dosing. The prescribed morning dose of dolutegravir is standard to optimize adherence and efficacy, making this statement incorrect. E. Doubling a missed dose is incorrect and potentially harmful. ART regimens require consistent dosing; patients should take the missed dose as soon as remembered unless it’s close to the next dose, to avoid toxicity and maintain efficacy. F. Taking ART with antacids is not recommended, as antacids can reduce dolutegravir absorption, decreasing its effectiveness. Patients should be advised to avoid antacids or follow specific timing guidelines, making this statement incorrect. G. CD4+T cell counts are a key measure of ART effectiveness, as they reflect immune system recovery. Monitoring CD4+T counts every 3 months, as ordered, assesses treatment success, making this statement correct for patient education. H. ART, including dolutegravir and lamivudine, does not cause wasting syndrome. Wasting syndrome is associated with untreated HIV or older regimens, not modern ART, making this statement incorrect for patient education.